Skip to main content

Home/ Medicine & Healthcare/ Group items tagged pubmed

Rss Feed Group items tagged

avivajazz  jazzaviva

PubMed || Advanced Search - 0 views

avivajazz  jazzaviva

Fatty acids, the immune response, and autoimmunity...[Lipids. 2003] - PubMed Result - 0 views

  •  
    Fatty acids, the immune response, and autoimmunity: a question of n-6 essentiality and the balance between n-6 and n-3.
avivajazz  jazzaviva

Decreased free testosterone and dehydroep... [J Sex Marital Ther. 2002] - PubMed - NCBI - 0 views

  •  
    "Decreased free testosterone and dehydroepiandrosterone-sulfate (DHEA-S) levels in women with decreased libido."
avivajazz  jazzaviva

Women with low libido: correlation o... [Int J Impot Res. 2005 Mar-Apr] - PubMed - NCBI - 0 views

  •  
    "Women with low libido: correlation of decreased androgen levels with female sexual function index"
avivajazz  jazzaviva

How many scientists fabricate and falsify research? [PLoS One. 2009] - 1 views

  •  
    The frequency with which scientists fabricate and falsify data, or commit other forms of scientific misconduct is a matter of controversy... Misconduct was reported more frequently by medical/pharmacological researchers than others...This metareview is a conservative estimate of the true prevalence of scientific misconduct.
avivajazz  jazzaviva

Recurrence rate of superficial basal cell carcinom... [Eur J Dermatol. 2008 Nov-Dec] - ... - 0 views

  •  
    The estimate of overall treatment success for all treated patients at the end of follow-up was 77.9% (80.9% considering histology). The data support clinical assessment of initial response as predictive of long-term outcome. Most of the recurrences occurred early, indicating that careful follow-up is important during the first year after treatment.
avivajazz  jazzaviva

Use of 5% imiquimod cream in the treatment of faci... [Australas J Dermatol. 2006] - Pu... - 0 views

  •  
    We found that 5% imiquimod cream is an effective treatment option for superficial and nodular basal cell carcinomas, giving a clearance rate of 89.5% at an average of 39 months of follow up.
avivajazz  jazzaviva

Management of superficial basal cell carcinoma: fo... [Clin Cosmet Investig Dermatol. 2... - 0 views

  •  
    To date one long-term study indicates a treatment success rate of 78%-81% and that initial response is a predictor of long-term outcome. Recurrences tend to occur within the first year after treatment. Future research will compare this preparation to the gold standard treatment for superficial BCC - surgical excision.
avivajazz  jazzaviva

Imiquimod 5% cream for the treatment of superficia... [J Am Acad Dermatol. 2004] - PubM... - 0 views

  •  
    Composite clearance rates (combined clinical and histological assessments) for the 5 and 7x/week imiquimod groups were 75% and 73%, respectively. Histological clearance rates for the 5 and 7x/week imiquimod groups were 82% and 79%, respectively. Increasing severity of erythema, erosion, and scabbing/crusting was associated with higher clearance rates. CONCLUSION: Imiquimod appears to be safe and effective for the treatment of sBCC when compared with vehicle cream. The difference in clearance rates between the two imiquimod dosing groups was not significant. The 5x/week regimen is recommended.
avivajazz  jazzaviva

Recurrence rate of superficial basal cell carcinom... [Eur J Dermatol. 2005 Sep-Oct] - ... - 0 views

  •  
    The initial sBCC clearance rate was 90% (12-week post treatment), whereas the proportion of subjects who were clinically clear at 2 years (current time point) was estimated to be 79.4%.
avivajazz  jazzaviva

Superficial basal cell carcinoma treated with imiquimod 5% topical cream for a 4-week p... - 0 views

  •  
    Clinical clearance rate at 1 and 2 years were 89% and 85%, respectively.
avivajazz  jazzaviva

Has imiquimod 5% cream a role in the management of... [Eur J Dermatol. 2009 Sep-Oct] - ... - 0 views

  •  
    Clinical clearance rate at 1, 2 and 3 years were 94, 76 and 70%, respectively. We conclude that imiquimod seems to be an appropriate therapeutic alternative for the treatment of recurrent BCC in patients with associated co-morbidities.
avivajazz  jazzaviva

Two-year interim results from a 5-year study evalu... [Australas J Dermatol. 2006] - Pu... - 0 views

  •  
    The proportion of subjects who were clinically clear at the 2-year follow-up visit was estimated to be 82.0%. Imiquimod was tolerated when applied daily, with erythema reported for all subjects participating in the study. The recurrence rate observed suggests that once daily dosing and 5x/week dosing yield similar clearance rates, but daily dosing increases local skin reactions.
avivajazz  jazzaviva

Treatment of cutaneous tumors with topical 5% imiq... [Clinics (Sao Paulo). 2009] - Pub... - 0 views

  •  
    For patients without comorbidities, the overall cure rate was 73%. For these patients, the cure rates were 85.7% for superficial and nodular BCC, 88% for superficial BCC, 57% for Bowen's disease, 50% for nodular BCC, and 50% for aggressive BCC.
1 - 20 of 84 Next › Last »
Showing 20 items per page